Biocytogen Announces RenLite® Licensing Agreement with Janssen
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") (HKEX: 02315), today announced the signing of a non-exclusive license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (“Janssen”). Under the agreement, Biocytogen grants Janssen and its affiliates a non-exclusive worldwide license to use Biocytogen’s proprietary RenLite® platform and underlying intellectual property to discover, research, develop, manufacture and commercialize fully human antibody therapeutics with a common light chain and other biological therapeutics for an unlimited number of drug targets and indications. The agreement was facilitated by Johnson & Johnson Innovation LLC.
RenLite® is a member of Biocytogen's fully human antibody RenMice™ family. RenLite® mice can generate fully human antibody candidates with high specificity, affinity, diversity and good druggability, with a common light chain for subsequent assembly of bispecific and multispecific antibodies with a low mismatch and high success rate. The bispecific and multispecific antibodies assembled after RenLite® discovery have a traditional antibody structure and exhibit ideal physiochemical properties that are advantageous for downstream CMC development.
Dr. Yuelei Shen, Founder, Chairman and CEO of Biocytogen, said: “We are pleased to partner with Janssen to accelerate the discovery of new antibody-based drugs for patients.”
About RenMice™
RenMice™ are Biocytogen’s proprietary genetically modified mice that generate antibodies with fully human variable domains. The models, which include RenMab™, RenLite® and RenNano® mouse platforms, as well as substrains containing additional modifications, were developed using Biocytogen’s size-unlimited, precise chromosome engineering technology (SUPCE), which allows for in situ replacement of the murine immunoglobulin genes with their human counterpart. All RenMice platforms contain the entire human heavy chain VDJ loci, with the RenMab mouse harboring all human light chain VJ loci. In contrast, the RenLite mouse contains a single human VJ locus in situ to facilitate future bispecific antibody assembly, while the RenNano mouse has modified heavy chain constant regions to generate functional heavy-chain-only antibodies (HCAbs).
RenMice can generate robust immune response and produce fully human antibodies with great diversity, specificity, affinity and druggability. The development of RenMice has allowed Biocytogen to launch 6 fully human antibody discovery platforms: monoclonal antibody (RenMab), bispecific antibody and bispecific ADC (RenLite), nanobody (RenNano), TCR-mimic antibody for intracellular targets (HLA/RenMice, i.e., MHC humanized RenMice), and a RenMice HiTS (hyperimmune target specific) antibody platform designed for GPCR and other challenging targets.
As of June 30, 2022, RenMice have been licensed by 16 biopharmaceutical companies around the world, including Merck KGaA, Xencor, BeiGene, and Innovent.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMab™/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, respectively, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. As of June 30, 2022, this project has resulted in 28 drug co-development agreements and 16 RenMice™ licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's internal pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005504/en/
Contact information
Biocytogen’s Contacts
Antibody platforms and antibody assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PsiQuantum to Build World’s First Utility-Scale, Fault-Tolerant Quantum Computer in Australia29.4.2024 23:00:00 EEST | Press release
PsiQuantum today announced it will build the world’s first utility-scale quantum computer at a strategically located site near Brisbane Airport in Brisbane, Australia. The Australian Commonwealth and Queensland Governments will invest $940M AUD ($620M USD) into PsiQuantum through a financial package, comprised of equity, grants, and loans. PsiQuantum is on an aggressive plan to have the site operational by the end of 2027. A fault-tolerant quantum computer will be able to solve commercially useful problems across industries built upon chemistry, math, and physics; thereby transforming critical industries – including renewable energy, minerals and metals, healthcare and transportation – that will propel the global economy for decades to come. The quantum computing industry has long faced complicated scaling challenges in building a quantum computer with enough physical qubits to enable error-correction, making it capable of delivering on quantum computing’s promise. PsiQuantum has scale
WHOOP Announces Significant Global Expansion, Appoints New Senior Leadership29.4.2024 21:10:00 EEST | Press release
WHOOP, the human performance company, today announced the expansion of its global footprint, now shipping to 56 markets worldwide, with more launches ahead. Additionally, the WHOOP app is now available in Italian and Spanish (Latin America), as well as English, French, and German. To support continued growth and momentum, WHOOP named new leaders to its C-suite to deliver on the WHOOP mission of helping people achieve their goals, by providing best-in-class wearable technology, actionable feedback, and recommendations across recovery, sleep, strain, and health. To help everyone start their journey, WHOOP is currently offering a one-month free trial that can be accessed on WHOOP.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429085870/en/ WHOOP announces significant global expansion, appoints new senior leadership. Continues "Free Trials," making it the only wearable to offer "Try Before You Buy." (Photo: Business Wire
The Transat CIC Started Yesterday: Alberto Bona and the Class40 IBSA in Fourth Position After 24 Hours of Navigation29.4.2024 19:57:00 EEST | Press release
A spectacular start, on Sunday, April 28 at 1:30 pm for the transoceanic regatta Transat CIC, one of the most demanding tests for solo sailors, who are called to face very tough conditions on their way to New York after over 3,000 miles of navigation, starting from Lorient, Brittany (France). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429033051/en/ Class40 IBSA - The Transat CIC © IBSA | Beppe Raso The 48 registered skippers – divided into the IMOCA (33, some equipped with foil), Class40 (13) and Vintage (2) categories – positioned themselves along the starting line, in the channel between the Breton coast, before the small town of Lomener, and the island of Groix. After heading South East, on a course designed by the regatta director with the aim of making the start of the transoceanic race spectacular and safe, the skippers began their ascent of the Breton coast. A conservative start for Alberto Bona on the Class40
DNB//Back Bay Announces Dates for the Nordic-American Healthcare Conference 202529.4.2024 19:00:00 EEST | Press release
DNB Markets (“DNB”) and Back Bay Life Science Advisors (“Back Bay"), acting through the DNB//Back Bay Healthcare Partnership are pleased to announce the dates for our highly anticipated 9th annual Nordic-American Healthcare Conference (NAHC). Hosted by DNB//Back Bay with Nasdaq Nordic, Innovation Norway and Business Sweden, this pre-eminent US-based Nordic healthcare equity investor event will convene in New York City on March 26–27, 2025, bringing together industry leaders, investors and innovators from across the global healthcare sector. Renowned for their excellence in life science development and commercial leadership, the Nordic markets offer a wealth of cutting-edge technologies that are shaping the future of global healthcare. Showcasing this dynamism, NAHC 2025 will offer focused tracks and panel discussions supported by DNB Markets’ recognized research analysts exploring specific industry developments that also reflect prominent capabilities in the Nordic region. NAHC 2025 wi
Todd Clegg Named Carestream’s Chief Executive Officer29.4.2024 17:15:00 EEST | Press release
Carestream, a world-leading provider of medical imaging systems and non-destructive testing solutions, announced that Todd Clegg has been named CEO and appointed to the Board of Directors, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240429960055/en/ Carestream CEO Todd Clegg (Photo: Business Wire) Mr. Clegg joined Carestream in October last year and has been the company’s interim CEO since December 1. “I am excited to continue in my role as leader of Carestream and to build upon the success we’ve had over the last six months,” he remarked. “Carestream has been a consistent leader in the healthcare and non-destructive testing markets with innovative products and solutions and we expect this to continue going forward. I also want to thank the Carestream team and Board for welcoming me into the organization and for their support getting me up to speed quickly and effectively.” Mr. Clegg is an experienc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom